OSEBX1,423.56+0.84%
EQNR284.60+4.20%
DNB198.35-1.15%
MOWI172.80+0.45%
Brent$71.24-0.32%
EUR/USD1.0824-0.14%
DXY104.18+0.08%
INDICATIVE · SAMPLE DATA
SOLA52

Solara Active Pharma Sciences Ltd

PharmaceuticalsVerified

Capital Structure and Liquidity Solara Active Pharma Sciences Ltd has a debt-to-equity ratio of 0.73, indicating a moderate level of leverage. The company's liquidity position is assessed as medium, with a current ratio of 0.77, suggesting that it may face challenges in meeting short-term obligations with its current assets. The company's free cash flow stands at 597.4 million INR, which is lower than its operating cash flow of 2,128.2 million INR, indicating that capital expenditures have consumed a significant portion of its operating cash flow. ### Profitability and Returns The company's profitability is modest, with a net income of 5.4 million INR and an operating income of 1,080.5 million INR. Its return on equity (ROE) is 0.05%, and return on assets (ROA) is 0.02%, both of which are below the industry median for pharmaceutical companies. These low returns suggest that the company is not effectively utilizing its equity and assets to generate profits. ### Segments and Geographic Exposure The company's revenue is concentrated in a single business segment, as disclosed in its financial statements. There is no detailed breakdown of geographic revenue distribution in the provided data, but the company's operations are primarily based in India, as indicated by the use of INR as the reporting currency. ### Growth Trajectory The company's revenue for the latest reporting period is 12,837.6 million INR. While the company has a positive free cash flow, the absence of historical revenue data makes it difficult to assess its growth trajectory. The analyst estimate for revenue is aligned with the reported figure, indicating that the company is meeting market expectations. ### Risk Factors The company faces a medium liquidity risk, as its current ratio is below 1, and it has a negative net cash position after accounting for total debt. The risk of dilution is assessed as low, with no significant dilution potential identified in the basic shares outstanding. The company's capital structure includes a long-term debt of 7,960.8 million INR, which could pose a refinancing risk if interest rates rise. ### Recent Events The most recent financial data available is from the latest market data filing, which includes the company's revenue and profitability figures. There are no additional filings or transcripts provided that would indicate recent strategic changes or operational developments.

30-day price · SOLA+68.45 (+14.1%)
Low$471.00High$606.40Close$554.25As of25 May, 00:00 UTC
Profile
CompanySolara Active Pharma Sciences Ltd
TickerSOLA.NS
SectorHealthcare
BusinessPharmaceuticals & Medical Research
Industry groupPharmaceuticals & Medical Research
IndustryPharmaceuticals
AI analysis

Business. (unavailable from LLM output)

Classification. (unavailable from LLM output)

### Capital Structure and Liquidity Solara Active Pharma Sciences Ltd has a debt-to-equity ratio of 0.73, indicating a moderate level of leverage. The company's liquidity position is assessed as medium, with a current ratio of 0.77, suggesting that it may face challenges in meeting short-term obligations with its current assets. The company's free cash flow stands at 597.4 million INR, which is lower than its operating cash flow of 2,128.2 million INR, indicating that capital expenditures have consumed a significant portion of its operating cash flow. ### Profitability and Returns The company's profitability is modest, with a net income of 5.4 million INR and an operating income of 1,080.5 million INR. Its return on equity (ROE) is 0.05%, and return on assets (ROA) is 0.02%, both of which are below the industry median for pharmaceutical companies. These low returns suggest that the company is not effectively utilizing its equity and assets to generate profits. ### Segments and Geographic Exposure The company's revenue is concentrated in a single business segment, as disclosed in its financial statements. There is no detailed breakdown of geographic revenue distribution in the provided data, but the company's operations are primarily based in India, as indicated by the use of INR as the reporting currency. ### Growth Trajectory The company's revenue for the latest reporting period is 12,837.6 million INR. While the company has a positive free cash flow, the absence of historical revenue data makes it difficult to assess its growth trajectory. The analyst estimate for revenue is aligned with the reported figure, indicating that the company is meeting market expectations. ### Risk Factors The company faces a medium liquidity risk, as its current ratio is below 1, and it has a negative net cash position after accounting for total debt. The risk of dilution is assessed as low, with no significant dilution potential identified in the basic shares outstanding. The company's capital structure includes a long-term debt of 7,960.8 million INR, which could pose a refinancing risk if interest rates rise. ### Recent Events The most recent financial data available is from the latest market data filing, which includes the company's revenue and profitability figures. There are no additional filings or transcripts provided that would indicate recent strategic changes or operational developments.
Key takeaways
  • Solara Active Pharma Sciences Ltd has a moderate level of leverage with a debt-to-equity ratio of 0.73.
  • The company's liquidity position is medium, with a current ratio of 0.77.
  • Profitability is weak, with a net income of 5.4 million INR and low ROE and ROA.
  • The company's revenue is concentrated in a single business segment, with no detailed geographic breakdown.
  • The company has a positive free cash flow but faces potential liquidity challenges due to its current ratio and net cash position.
  • --
  • ## RATIONALES
  • ```json
Financial snapshot
PeriodHA-latest
CurrencyINR
Revenue$12.84B
Gross profit$5.47B
Operating income$1.08B
Net income$5.4M
R&D
SG&A
D&A
SBC
Operating cash flow$2.13B
CapEx-$399.4M
Free cash flow$597.4M
Total assets$22.32B
Total liabilities$11.38B
Total equity$10.94B
Cash & equivalents
Long-term debt$7.96B
Valuation
Market price
Market cap
Enterprise value
P/E
Reported non-GAAP P/E
EV/Revenue
EV/Op income
EV/OCF
P/B
P/Tangible book
Tangible book$10.94B
Net cash-$7.96B
Current ratio0.8
Debt/Equity0.7
ROA0.0%
ROE0.1%
Cash conversion394.1%
CapEx/Revenue-3.1%
SBC/Revenue
Asset intensity
Dilution ratio0.0%
Risk assessment
Dilution riskLow
Liquidity riskMedium
  • Net cash is negative after subtracting total debt.
Industry benchmarks
Activity: Pharmaceuticals · cohort 779 companies
MetricSOLAActivity
Op margin8.4%7.7% medp25 -2.4% · p75 15.5%above median
Net margin0.0%5.9% medp25 -3.8% · p75 12.8%below median
Gross margin42.6%45.5% medp25 31.1% · p75 62.9%below median
R&D / revenue529.2% medp25 465.2% · p75 593.2%
CapEx / revenue-3.1%-7.0% medp25 -14.9% · p75 -3.2%top quartile
Debt / equity73.0%25.0% medp25 3.8% · p75 63.3%top quartile
Observations
IR observations
Last actual revenue12,837,600,000 INR
Source data
Underlying data the analysis-pipeline pulls and audits. Fetch timestamps + content hashes show when each source was last refreshed.
Company fundamentalsperiod financials
no public URL
2026-05-24 18:15 UTC#2f4fd5d6
Source: analysis-pipeline (hybrid)Generated: 2026-05-29 12:35 UTCJob: 334183a7